NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

被引：0
|
作者：
Gregorc, V. [1 ]
Ceresoli, G. L. [2 ]
Zucali, P. A. [2 ]
De Braud, F. G. [3 ]
Bajetta, E. [4 ]
Santoro, A. [2 ]
Vigano, M. G. [1 ]
Cappio, F. Caligaris [1 ]
Lambiase, A. [5 ]
Bordignon, C. [5 ]
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Ist Clin Humanitas, Dept Oncol, Milan, Italy
[3] Ist Europeo Oncol, Clin Pharmacol & New Drugs Unit, Milan, Italy
[4] IRCCS Fdn, Ist Nazl Tumori, Dept Oncol, Milan, Italy
[5] MolMed, Clin Dev, Milan, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71724-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 509
页数：1
相关论文
共 50 条
  • [21] Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens
    Sobrero, A. F.
    Pessino, A.
    Andretta, V.
    Bennicelli, E.
    Fornarini, G.
    Caprioni, F.
    Comandini, D.
    Orsino, L.
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 341 - 341
  • [22] Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)
    Gregorc, V.
    Novello, S.
    Santoro, A.
    Grossi, F.
    Levra, M. Giaj
    Cavina, R.
    Vigano, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
    Santoro, Armando
    Rimassa, Lorenza
    Sobrero, Alberto F.
    Citterio, Giovanni
    Sclafani, Francesco
    Carnaghi, Carlo
    Pessino, Anna
    Caprioni, Francesco
    Andretta, Valeria
    Tronconi, Maria Chiara
    Finocchiaro, Giovanna
    Rossoni, Gloria
    Zanoni, Angela
    Miggiano, Chiara
    Rizzardi, Gian-Paolo
    Traversari, Catia
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2746 - 2752
  • [24] A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] PHASE IB STUDY TO DEFINE THE OPTIMAL LOW DOSE OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), IN COMBINATION WITH CISPLATIN IN PATIENTS (PTS) WITH SOLID TUMOURS
    Gregorc, V.
    De Braud, F. G.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 160
  • [26] NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3
    Gregorc, Vanesa
    Gaafar, Rabab M.
    Favaretto, Adolfo
    Grossi, Francesco
    Jassem, Jacek
    Polychronis, Andreas
    Bidoli, Paolo
    Tiseo, Marcello
    Shah, Riyaz
    Taylor, Paul
    Novello, Silvia
    Muzio, Alberto
    Bearz, Alessandra
    Greillier, Laurent
    Fontana, Floriana
    Salini, Giulia
    Lambiase, Antonio
    O'Brien, Mary
    LANCET ONCOLOGY, 2018, 19 (06): : 799 - 811
  • [27] Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
    Gregorc, Vanesa
    De Braud, Filippo G.
    De Pas, Tommaso M.
    Scalamogna, Roberto
    Citterio, Giovanni
    Milani, Alessandra
    Boselli, Sabrina
    Catania, Chiara
    Donadoni, Giovanni
    Rossoni, Gilda
    Ghio, Domenico
    Spitaleri, Gianluca
    Ammannati, Cristina
    Colombi, Scialini
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1964 - 1972
  • [28] Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
    Ikeda, Takaya
    Takemoto, Shinnosuke
    Senju, Hiroaki
    Gyotoku, Hiroshi
    Taniguchi, Hirokazu
    Shimada, Midori
    Dotsu, Yosuke
    Umeyama, Yasuhiro
    Tomono, Hiromi
    Kitazaki, Takeshi
    Fukuda, Masaaki
    Soda, Hiroshi
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Mukae, Hiroshi
    THORACIC CANCER, 2020, 11 (07) : 1972 - 1978
  • [29] Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).
    Gregorc, Vanesa
    Bulotta, Alessandra
    Vigano, Maria G.
    Citterio, Giovanni
    Petrella, Giovanna
    Brioschi, Elena
    Ducceschi, Monika
    Gianni, Luca
    Colombi, Scialini
    Rossoni, Gloria
    Salini, Giulia
    Savia, Veronica
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Bulotta, A.
    Vigano, M. G.
    Citterio, G.
    Petrella, G.
    Brioschi, E.
    Ducceschi, M.
    Gianni, L.
    Colombi, S.
    Rossoni, G.
    Salini, G.
    Savia, V.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2016, 27
12345